Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trialAndrew McGarry, Karl Kieburtz, Jordan Dubow et al.|The Lancet Neurology|2023Cited by 128
A Randomized Phase 3 Study Comparing <scp>P2B001</scp> to its Components (Low‐Dose Extended‐Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended‐Release Pramipexole in Early Parkinson's DiseaseC. Warren Olanow, Andrew McGarry, Ramon Gil et al.|Movement Disorders|2023Cited by 5